335 related articles for article (PubMed ID: 19638649)
1. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study.
Castle PE; Rodríguez AC; Burk RD; Herrero R; Wacholder S; Alfaro M; Morales J; Guillen D; Sherman ME; Solomon D; Schiffman M;
BMJ; 2009 Jul; 339():b2569. PubMed ID: 19638649
[TBL] [Abstract][Full Text] [Related]
2. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,
Bratti MC; Rodríguez AC; Schiffman M; Hildesheim A; Morales J; Alfaro M; Guillén D; Hutchinson M; Sherman ME; Eklund C; Schussler J; Buckland J; Morera LA; Cárdenas F; Barrantes M; Pérez E; Cox TJ; Burk RD; Herrero R
Rev Panam Salud Publica; 2004 Feb; 15(2):75-89. PubMed ID: 15030652
[TBL] [Abstract][Full Text] [Related]
3. Viral determinants of human papillomavirus persistence following loop electrical excision procedure treatment for cervical intraepithelial neoplasia grade 2 or 3.
Kreimer AR; Katki HA; Schiffman M; Wheeler CM; Castle PE;
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):11-6. PubMed ID: 17220326
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.
Rodríguez AC; Schiffman M; Herrero R; Hildesheim A; Bratti C; Sherman ME; Solomon D; Guillén D; Alfaro M; Morales J; Hutchinson M; Katki H; Cheung L; Wacholder S; Burk RD
J Natl Cancer Inst; 2010 Mar; 102(5):315-24. PubMed ID: 20157096
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease.
Kreimer AR; Guido RS; Solomon D; Schiffman M; Wacholder S; Jeronimo J; Wheeler CM; Castle PE
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):908-14. PubMed ID: 16702369
[TBL] [Abstract][Full Text] [Related]
6. Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result.
Strang THR; Gottschlich A; Cook DA; Smith LW; Gondara L; Franco EL; van Niekerk DJ; Ogilvie GS; Krajden M
Am J Obstet Gynecol; 2021 Nov; 225(5):511.e1-511.e7. PubMed ID: 34081897
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
8. Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3.
Rodríguez AC; Schiffman M; Herrero R; Hildesheim A; Bratti C; Sherman ME; Solomon D; Guillén D; Alfaro M; Morales J; Hutchinson M; Cheung L; Wacholder S; Burk RD
Int J Cancer; 2012 Oct; 131(8):1874-81. PubMed ID: 22213126
[TBL] [Abstract][Full Text] [Related]
9. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
[TBL] [Abstract][Full Text] [Related]
10. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.
Castle PE; Gravitt PE; Solomon D; Wheeler CM; Schiffman M
J Clin Microbiol; 2008 Jan; 46(1):109-17. PubMed ID: 17989194
[TBL] [Abstract][Full Text] [Related]
11. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection.
Keller MJ; Burk RD; Xie X; Anastos K; Massad LS; Minkoff H; Xue X; D'Souza G; Watts DH; Levine AM; Castle PE; Colie C; Palefsky JM; Strickler HD
JAMA; 2012 Jul; 308(4):362-9. PubMed ID: 22820789
[TBL] [Abstract][Full Text] [Related]
12. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
[TBL] [Abstract][Full Text] [Related]
13. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.
Ouh YT; Min KJ; Cho HW; Ki M; Oh JK; Shin SY; Hong JH; Lee JK
J Gynecol Oncol; 2018 Jan; 29(1):e14. PubMed ID: 29185272
[TBL] [Abstract][Full Text] [Related]
15. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project.
Herrero R; Schiffman MH; Bratti C; Hildesheim A; Balmaceda I; Sherman ME; Greenberg M; Cárdenas F; Gómez V; Helgesen K; Morales J; Hutchinson M; Mango L; Alfaro M; Potischman NW; Wacholder S; Swanson C; Brinton LA
Rev Panam Salud Publica; 1997 May; 1(5):362-75. PubMed ID: 9180057
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus genotypes and risk of persistence and progression in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2.
Damgaard RK; Jenkins D; Stoler MH; de Koning M; van de Sandt M; Lycke KD; Kahlert J; Gravitt PE; Quint WGV; Steiniche T; Petersen LK; Hammer A
Am J Obstet Gynecol; 2024 Jun; 230(6):655.e1-655.e10. PubMed ID: 38336125
[TBL] [Abstract][Full Text] [Related]
17. A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus-positive and -Negative Cervical Precancers.
Castle PE; Pierz AJ; Adcock R; Aslam S; Basu PS; Belinson JL; Cuzick J; El-Zein M; Ferreccio C; Firnhaber C; Franco EL; Gravitt PE; Isidean SD; Lin J; Mahmud SM; Monsonego J; Muwonge R; Ratnam S; Safaeian M; Schiffman M; Smith JS; Swarts A; Wright TC; Van De Wyngard V; Xi LF
Cancer Prev Res (Phila); 2020 Oct; 13(10):829-840. PubMed ID: 32655005
[TBL] [Abstract][Full Text] [Related]
18. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease.
Gravitt PE; Kovacic MB; Herrero R; Schiffman M; Bratti C; Hildesheim A; Morales J; Alfaro M; Sherman ME; Wacholder S; Rodriguez AC; Burk RD
Int J Cancer; 2007 Dec; 121(12):2787-93. PubMed ID: 17722112
[TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
[TBL] [Abstract][Full Text] [Related]
20. Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancer.
Safaeian M; Hildesheim A; Gonzalez P; Yu K; Porras C; Li Q; Rodriguez AC; Sherman ME; Schiffman M; Wacholder S; Burk R; Herrero R; Burdette L; Chanock SJ; Wang SS
PLoS One; 2012; 7(4):e33619. PubMed ID: 22496757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
